RxDoctor Payments Data

Hooman Kashani, DO

Nephrology · Encino, CANPI 1124117452

Payments from drug & device makers

$1,159in general payments, 2019–2025

Across 35 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$314
  • Amgen$246
  • Vifor Pharma, Inc.$200
  • Regeneron Healthcare Solutions, Inc.$118
  • Nxstage Medical, Inc.$100
  • Novartis$69
  • plus $112 from 3 others

What the payments were for

  • Speaking & faculty fees$20017%
  • Food & beverage$95983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,159 in reported general payments places this provider in the 45th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$902,931
Medicare patients
491
Services billed
8,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban316$103,043
Sevelamer Hcl55$44,751
VelphoroSucroferric Oxyhydroxide18$39,817
Sevelamer Carbonate74$26,855
EntrestoSacubitril/Valsartan70$24,281
Cinacalcet Hcl22$22,528
RetacritEpoetin Alfa-Epbx19$20,142
JardianceEmpagliflozin26$14,881
SantylCollagenase Clostridium Hist.12$13,398
ProcritEpoetin Alfa12$13,108
TradjentaLinagliptin35$13,062
Enoxaparin Sodium120$12,229
LokelmaSodium Zirconium Cyclosilicate20$12,135
Pantoprazole Sodium157$10,701
Diclofenac Sodium36$9,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$37$39,81718 claims
NovartisEntresto$69$24,28170 claims
AmgenEpogen$246$7,44619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,341 nephrology providers in California.

Other nephrology in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →